ALLMedicine™ Acute Bronchospasm Center

Feb 2nd, 2023 - Acute bronchospasm associated with exacerbations of asthma is a common problem. Currently the mainstay of treatment is inhalation albuterol, either levalbuterol or racemic mixture, in repetitive fashion depending on the resolution of the airways o...

Apr 11th, 2022 - Approach Considerations Management of toxic exposure to ammonia is largely supportive. Decontaminate the patient (if that was not done at the site of exposure) and support airway, breathing, and circulation (ABCs) as necessary. Provide warmed humi...

May 4th, 2021 - BACKGROUND Although rare, atrial myxoma is the most common benign cardiac tumor. The recognized triad of presenting symptoms relates to constitutional, embolic, and obstructive effects produced by the tumor. However, the presentation may be non-sp...

Mar 9th, 2021 - Bronchospasm in children is common; however, due to its sudden nature, radiographic correlation is uncommon. We planned a computed tomography (CT) coronary angiogram for a 5-year-old child for evaluation of Kawasaki disease. The child started to d...

Feb 10th, 2020 - Reference Range Theophylline is a methylxanthine, a class of molecule similar to the xanthines caffeine and theobromine found in a normal diet. [1, 2] It has a half-life of 8 hours in a healthy person but decreases to 4-5 hours in people who smoke...

Feb 2nd, 2023 - Acute bronchospasm associated with exacerbations of asthma is a common problem. Currently the mainstay of treatment is inhalation albuterol, either levalbuterol or racemic mixture, in repetitive fashion depending on the resolution of the airways o...

Jun 24th, 2019 - Chronic obstructive pulmonary disease (COPD) is a major cause of illness and death. In fact, by 2020, the World Health Organization predicts that COPD will become the third leading cause of death (currently fourth), and the fifth leading cause of ...

Dec 22nd, 2016 - Despite few scientific evidence that could support the use of ketamine in adult patients undergoing acute bronchospasm requiring mechanical ventilation (MV), ketamine is largely employed in this setting. The aim of this study is therefore assess m...

Apr 8th, 2016 - This is a study to determine the safety and tolerability of cumulative dosing with levalbuterol tartrate HFA inhalation aerosol MDI using a valved holding chamber and facemask in pediatric subjects birth to ≤ 48 months of age with acute bronchospa...

Jun 23rd, 2011 - Beta-blockers are indicated in the management of numerous medical conditions including angina pectoris, myocardial infarction, hypertension, congestive heart failure, cardiac arrhythmia, systemic hypertension, as well as to reduce complications in...

Dec 20th, 2021 - The FDA approved the only biologic for severe asthma without any phenotype or biomarker limitations, manufacturers AstraZeneca and Amgen announced Friday. The first-in-class biologic tezepelumab-ekko (Tezspire) is indicated as an add-on maintenanc...

Oct 4th, 2019 - The Food and Drug Administration has approved a prefilled, single-use autoinjector of benralizumab (Fasenra) for self-administration in adults with eosinophilic asthma, according to a press release from AstraZeneca. Benralizumab is already approve.

Oct 4th, 2019 - The Food and Drug Administration has approved a prefilled, single-use autoinjector of benralizumab (Fasenra) for self-administration in adults with eosinophilic asthma, according to a press release from AstraZeneca. Benralizumab is already approve.

Sep 13th, 2019 - The Food and Drug Administration has approved mepolizumab (Nucala, 40 mg subcutaneous) for patients aged 6-11 years with severe eosinophilic asthma, according to a release from GlaxoSmithKline, which developed the drug. This is the first targeted.

Jun 6th, 2019 - The Food and Drug Administration has approved two new formulations for the anti–interleukin-5 biologic mepolizumab (Nucala) for treatment of certain severe or rare forms of asthma, according to a press release from the drug’s developer. The biolog.